IMUGENE LIMITED - Announcements

Market Cap $548.9M Add to my watchlist

Healthcare Biotechnology

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing... Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs. More

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care.

Announcements

Filter Results

All Price Sensitive Only

IMU	Half Yearly Report and Accounts	PRICE SENSITIVE	26/02/20	5.84MB	Share
IMU	Ceasing to be a substantial holder		13/02/20	87.8KB	Share
IMU	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/20	348.47KB	Share
IMU	Imugene PD1-Vaxx Immunotherapy Update	PRICE SENSITIVE	28/01/20	138.09KB	Share
IMU	Imugene HER-Vaxx Immunotherapy Patent Granted in US	PRICE SENSITIVE	14/01/20	123.55KB	Share
IMU	Completion of Less Than Marketable Parcel Sale		24/12/19	97.24KB	Share
IMU	Appendix 3B and Required LR 3.10.5A Information		06/12/19	564.42KB	Share
IMU	Imugene appoints Dr R Auer to Oncolytic Virotherapy SAB		05/12/19	156.53KB	Share
IMU	Prospectus	PRICE SENSITIVE	02/12/19	556.91KB	Share
IMU	Investor Presentation		02/12/19	3.07MB	Share
IMU	Imugene Share Placement to raise $24.6 million	PRICE SENSITIVE	02/12/19	134.16KB	Share
IMU	Change of Director's Interest Notice - PH		28/11/19	218.65KB	Share
IMU	Trading Halt	PRICE SENSITIVE	28/11/19	360.08KB	Share
IMU	Appendix 3B and 708A Notice		28/11/19	500.45KB	Share
IMU	Change of Director's Interest Notice - CW		27/11/19	171.01KB	Share
IMU	CF33 Oncolytic Virus GMP Manufacturing Update		25/11/19	84.79KB	Share
IMU	Imugene appoints Prof Prasad S Adusumilli of MSKCC to OV SAB		20/11/19	130.96KB	Share
IMU	Change of Director's Interest Notice - JE		19/11/19	168.81KB	Share
IMU	Change of Director's Interest Notice - LR		19/11/19	169.1KB	Share
IMU	Change of Director's Interest Notice - CW		19/11/19	171KB	Share
IMU	Change of Director's Interest Notice - AH		19/11/19	169.13KB	Share
IMU	Results of Meeting - Oncolytic Virus Acquisition Complete		18/11/19	187.67KB	Share
IMU	Appendix 3B		15/11/19	358.23KB	Share
IMU	Imugene Extraordinary General Meeting Call Details		11/11/19	103.61KB	Share
IMU	Results of Meeting		08/11/19	179.92KB	Share
IMU	AGM Presentation		08/11/19	2.47MB	Share
IMU	Imugene Annual General Meeting Call Details		07/11/19	103.96KB	Share
IMU	Investor Presentation - November 2019		06/11/19	5.92MB	Share
IMU	Imugene Receives $4.13 million R&D Tax Incentive	PRICE SENSITIVE	04/11/19	103.43KB	Share
IMU	Appendix 4C - quarterly	PRICE SENSITIVE	25/10/19	389.27KB	Share
IMU	US Defense Grant to Study Imugene CF33 Oncolytic Virotherapy	PRICE SENSITIVE	23/10/19	246.29KB	Share
IMU	Change of Director's Interest Notice - AH		21/10/19	271.98KB	Share
IMU	CF33 Oncolytic Virus Clinical Trial Program Update	PRICE SENSITIVE	21/10/19	86.78KB	Share
IMU	Appendix 3B and 708A Notice		18/10/19	486.55KB	Share
IMU	Yuman Fong, MD to Chair Imugene Oncolytic Virotherapy SAB		17/10/19	137.18KB	Share
IMU	Notice of Extraordinary General Meeting/Proxy Form		14/10/19	1.79MB	Share
IMU	Notice of UMP Facility to Eligible Shareholders		09/10/19	100.35KB	Share
IMU	Share Sale Facility for Holders of Unmarketable Parcels		04/10/19	1.07MB	Share
IMU	Notice of Annual General Meeting/Proxy Form		04/10/19	772.1KB	Share
IMU	Imugene Cancer Vaccine Combinations Presented at ESMO		01/10/19	161.76KB	Share
IMU	Comprehensive Phase Ib HER-Vaxx Results Presented at ESMO	PRICE SENSITIVE	01/10/19	156.74KB	Share
IMU	Appendix 4G		30/08/19	217.23KB	Share
IMU	Corporate Governance Statement		30/08/19	189.29KB	Share
IMU	Appendix 4E & Annual Report to shareholders	PRICE SENSITIVE	30/08/19	5.25MB	Share
IMU	Appendix 4C - quarterly	PRICE SENSITIVE	26/07/19	247.66KB	Share
IMU	2019 Bioshares Presentation		26/07/19	6.47MB	Share
IMU	Investor update call details		15/07/19	309.96KB	Share
IMU	Investor Presentation - Proposed Acquisition	PRICE SENSITIVE	15/07/19	7.06MB	Share
IMU	Imugene Enhances Portfolio with Compelling Oncolytic Virus	PRICE SENSITIVE	15/07/19	91.67KB	Share
IMU	New HER-Vaxx Cancer Vaccine trial data presented at ESMO GI	PRICE SENSITIVE	08/07/19	79.11KB	Share
IMU	Appendix 3B and 708A Notice		27/06/19	492.06KB	Share
IMU	Updated Phase 1b HER-Vaxx data presented at ASCO		04/06/19	142.27KB	Share
IMU	Initial Director's Interest Notice - JE		20/05/19	192.76KB	Share
IMU	Global Biotechnology & VC Executive Joins Imugene Board		20/05/19	101.24KB	Share
IMU	Investor Presentation		01/05/19	5.38MB	Share
IMU	New Cancer Vaccine Trial Data presented at ASCO 2019		29/04/19	83.34KB	Share
IMU	Initial Director's Interest Notice - LR		23/04/19	190.93KB	Share
IMU	Leading Global Pharmaceutical Executive Joins Imugene Board		23/04/19	95.87KB	Share
IMU	Appendix 4C - Quarterly and Business Update	PRICE SENSITIVE	16/04/19	270.77KB	Share
IMU	Investor Presentation		16/04/19	6.3MB	Share
IMU	IMU presents new mimotope PD-1 vaccine data at AACR	PRICE SENSITIVE	03/04/19	160.49KB	Share
IMU	IMU presents new KEY-Vaxx and B-Vaxx data at AACR	PRICE SENSITIVE	02/04/19	164.88KB	Share
IMU	IMU presents positive new HER-Vaxx data at AACR	PRICE SENSITIVE	02/04/19	167.49KB	Share
IMU	Investor Presentation		26/03/19	1011.46KB	Share
IMU	IMU Pre-IND FDA Meeting Provides Guidance for KEY-Vaxx	PRICE SENSITIVE	20/03/19	75.86KB	Share
IMU	Imugene doses first patient in HER-Vaxx phase 2 trial	PRICE SENSITIVE	14/03/19	96.99KB	Share
IMU	IMU Announces Presentations on KEY-Vaxx and B-Vaxx at AACR	PRICE SENSITIVE	04/03/19	100.39KB	Share
IMU	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/19	4.58MB	Share
IMU	Pause in Trading	PRICE SENSITIVE	28/02/19	116KB	Share
IMU	Imugene Announces Presentation on HER-Vaxx at the AACR 2019	PRICE SENSITIVE	28/02/19	85.19KB	Share
IMU	Clinical Cancer Research Journal publish B-Vaxx Phase 1 Data		26/02/19	90.3KB	Share
IMU	Appendix 4C - Quarterly and Business Update	PRICE SENSITIVE	30/01/19	557.58KB	Share
IMU	Investor Presentation	PRICE SENSITIVE	10/01/19	11.83MB	Share
IMU	IMU appoints distinguished scientist to the Company SAB		07/01/19	372.6KB	Share
IMU	Change of Director's Interest Notice - PH		20/12/18	369.38KB	Share
IMU	IMU Meets Endpoints in Phase 1b Gastric Cancer Trial	PRICE SENSITIVE	17/12/18	114.47KB	Share
IMU	Change of Director's Interest Notice - LC		21/11/18	170.05KB	Share
IMU	Appendix 3B and 708A Notice		21/11/18	595.93KB	Share
IMU	Change of Director's Interest Notice - PH		21/11/18	170.4KB	Share
IMU	Results of Meeting		13/11/18	380.8KB	Share
IMU	AGM Presentation		13/11/18	2.26MB	Share
IMU	Imugene Advances to Phase 2 in Gastric Cancer Trial	PRICE SENSITIVE	13/11/18	366.09KB	Share
IMU	Imugene Receives $1.85 million R&D Tax Incentive	PRICE SENSITIVE	09/11/18	101.15KB	Share
IMU	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/18	1.05MB	Share
IMU	Change of Director's Interest Notice - AH		22/10/18	469.22KB	Share
IMU	Appendix 3B (Exercise of Options) and 708A Notice		22/10/18	538.73KB	Share
IMU	Notice of Annual General Meeting/Proxy Form		09/10/18	808.28KB	Share
IMU	Change in Executive Remuneration		08/10/18	343.88KB	Share
IMU	ESMO President joins Imugene Scientific Advisory Board		04/10/18	132.33KB	Share
IMU	Imugene appoints leading cancer researcher to SAB		01/10/18	318.23KB	Share
IMU	Appendix 4G		28/09/18	162.44KB	Share
IMU	Annual Report to shareholders		28/09/18	4.01MB	Share
IMU	Imugene commences cGMP manufacture of PD-1 cancer vaccine	PRICE SENSITIVE	21/09/18	141.95KB	Share
IMU	Imugene appoints gastrointestinal cancer expert to SAB		18/09/18	59.89KB	Share
IMU	Imugene Completes Phase 1b Cancer Vaccine Trial Recruitment	PRICE SENSITIVE	11/09/18	393.79KB	Share
IMU	Appendix 4E and Audited Financial Report	PRICE SENSITIVE	31/08/18	539.83KB	Share
IMU	Imugene appoints Dr Mark Marino Chief Medical Officer		23/08/18	399.43KB	Share
IMU	Appendix 4C - Quarterly and Business Update	PRICE SENSITIVE	31/07/18	555.82KB	Share
IMU	2018 Bioshares Presentation		27/07/18	5.08MB	Share
IMU	Change of Director's Interest Notice - LC		24/07/18	36.75KB	Share

IMU Half Yearly Report and Accounts
26/02/20	PRICE SENSITIVE	5.84MB	Share
IMU Ceasing to be a substantial holder
13/02/20		87.8KB	Share
IMU Appendix 4C - quarterly
31/01/20	PRICE SENSITIVE	348.47KB	Share
IMU Imugene PD1-Vaxx Immunotherapy Update
28/01/20	PRICE SENSITIVE	138.09KB	Share
IMU Imugene HER-Vaxx Immunotherapy Patent Granted in US
14/01/20	PRICE SENSITIVE	123.55KB	Share
IMU Completion of Less Than Marketable Parcel Sale
24/12/19		97.24KB	Share
IMU Appendix 3B and Required LR 3.10.5A Information
06/12/19		564.42KB	Share
IMU Imugene appoints Dr R Auer to Oncolytic Virotherapy SAB
05/12/19		156.53KB	Share
IMU Prospectus
02/12/19	PRICE SENSITIVE	556.91KB	Share
IMU Investor Presentation
02/12/19		3.07MB	Share
IMU Imugene Share Placement to raise $24.6 million
02/12/19	PRICE SENSITIVE	134.16KB	Share
IMU Change of Director's Interest Notice - PH
28/11/19		218.65KB	Share
IMU Trading Halt
28/11/19	PRICE SENSITIVE	360.08KB	Share
IMU Appendix 3B and 708A Notice
28/11/19		500.45KB	Share
IMU Change of Director's Interest Notice - CW
27/11/19		171.01KB	Share
IMU CF33 Oncolytic Virus GMP Manufacturing Update
25/11/19		84.79KB	Share
IMU Imugene appoints Prof Prasad S Adusumilli of MSKCC to OV SAB
20/11/19		130.96KB	Share
IMU Change of Director's Interest Notice - JE
19/11/19		168.81KB	Share
IMU Change of Director's Interest Notice - LR
19/11/19		169.1KB	Share
IMU Change of Director's Interest Notice - CW
19/11/19		171KB	Share
IMU Change of Director's Interest Notice - AH
19/11/19		169.13KB	Share
IMU Results of Meeting - Oncolytic Virus Acquisition Complete
18/11/19		187.67KB	Share
IMU Appendix 3B
15/11/19		358.23KB	Share
IMU Imugene Extraordinary General Meeting Call Details
11/11/19		103.61KB	Share
IMU Results of Meeting
08/11/19		179.92KB	Share
IMU AGM Presentation
08/11/19		2.47MB	Share
IMU Imugene Annual General Meeting Call Details
07/11/19		103.96KB	Share
IMU Investor Presentation - November 2019
06/11/19		5.92MB	Share
IMU Imugene Receives $4.13 million R&D Tax Incentive
04/11/19	PRICE SENSITIVE	103.43KB	Share
IMU Appendix 4C - quarterly
25/10/19	PRICE SENSITIVE	389.27KB	Share
IMU US Defense Grant to Study Imugene CF33 Oncolytic Virotherapy
23/10/19	PRICE SENSITIVE	246.29KB	Share
IMU Change of Director's Interest Notice - AH
21/10/19		271.98KB	Share
IMU CF33 Oncolytic Virus Clinical Trial Program Update
21/10/19	PRICE SENSITIVE	86.78KB	Share
IMU Appendix 3B and 708A Notice
18/10/19		486.55KB	Share
IMU Yuman Fong, MD to Chair Imugene Oncolytic Virotherapy SAB
17/10/19		137.18KB	Share
IMU Notice of Extraordinary General Meeting/Proxy Form
14/10/19		1.79MB	Share
IMU Notice of UMP Facility to Eligible Shareholders
09/10/19		100.35KB	Share
IMU Share Sale Facility for Holders of Unmarketable Parcels
04/10/19		1.07MB	Share
IMU Notice of Annual General Meeting/Proxy Form
04/10/19		772.1KB	Share
IMU Imugene Cancer Vaccine Combinations Presented at ESMO
01/10/19		161.76KB	Share
IMU Comprehensive Phase Ib HER-Vaxx Results Presented at ESMO
01/10/19	PRICE SENSITIVE	156.74KB	Share
IMU Appendix 4G
30/08/19		217.23KB	Share
IMU Corporate Governance Statement
30/08/19		189.29KB	Share
IMU Appendix 4E & Annual Report to shareholders
30/08/19	PRICE SENSITIVE	5.25MB	Share
IMU Appendix 4C - quarterly
26/07/19	PRICE SENSITIVE	247.66KB	Share
IMU 2019 Bioshares Presentation
26/07/19		6.47MB	Share
IMU Investor update call details
15/07/19		309.96KB	Share
IMU Investor Presentation - Proposed Acquisition
15/07/19	PRICE SENSITIVE	7.06MB	Share
IMU Imugene Enhances Portfolio with Compelling Oncolytic Virus
15/07/19	PRICE SENSITIVE	91.67KB	Share
IMU New HER-Vaxx Cancer Vaccine trial data presented at ESMO GI
08/07/19	PRICE SENSITIVE	79.11KB	Share
IMU Appendix 3B and 708A Notice
27/06/19		492.06KB	Share
IMU Updated Phase 1b HER-Vaxx data presented at ASCO
04/06/19		142.27KB	Share
IMU Initial Director's Interest Notice - JE
20/05/19		192.76KB	Share
IMU Global Biotechnology & VC Executive Joins Imugene Board
20/05/19		101.24KB	Share
IMU Investor Presentation
01/05/19		5.38MB	Share
IMU New Cancer Vaccine Trial Data presented at ASCO 2019
29/04/19		83.34KB	Share
IMU Initial Director's Interest Notice - LR
23/04/19		190.93KB	Share
IMU Leading Global Pharmaceutical Executive Joins Imugene Board
23/04/19		95.87KB	Share
IMU Appendix 4C - Quarterly and Business Update
16/04/19	PRICE SENSITIVE	270.77KB	Share
IMU Investor Presentation
16/04/19		6.3MB	Share
IMU IMU presents new mimotope PD-1 vaccine data at AACR
03/04/19	PRICE SENSITIVE	160.49KB	Share
IMU IMU presents new KEY-Vaxx and B-Vaxx data at AACR
02/04/19	PRICE SENSITIVE	164.88KB	Share
IMU IMU presents positive new HER-Vaxx data at AACR
02/04/19	PRICE SENSITIVE	167.49KB	Share
IMU Investor Presentation
26/03/19		1011.46KB	Share
IMU IMU Pre-IND FDA Meeting Provides Guidance for KEY-Vaxx
20/03/19	PRICE SENSITIVE	75.86KB	Share
IMU Imugene doses first patient in HER-Vaxx phase 2 trial
14/03/19	PRICE SENSITIVE	96.99KB	Share
IMU IMU Announces Presentations on KEY-Vaxx and B-Vaxx at AACR
04/03/19	PRICE SENSITIVE	100.39KB	Share
IMU Half Yearly Report and Accounts
28/02/19	PRICE SENSITIVE	4.58MB	Share
IMU Pause in Trading
28/02/19	PRICE SENSITIVE	116KB	Share
IMU Imugene Announces Presentation on HER-Vaxx at the AACR 2019
28/02/19	PRICE SENSITIVE	85.19KB	Share
IMU Clinical Cancer Research Journal publish B-Vaxx Phase 1 Data
26/02/19		90.3KB	Share
IMU Appendix 4C - Quarterly and Business Update
30/01/19	PRICE SENSITIVE	557.58KB	Share
IMU Investor Presentation
10/01/19	PRICE SENSITIVE	11.83MB	Share
IMU IMU appoints distinguished scientist to the Company SAB
07/01/19		372.6KB	Share
IMU Change of Director's Interest Notice - PH
20/12/18		369.38KB	Share
IMU IMU Meets Endpoints in Phase 1b Gastric Cancer Trial
17/12/18	PRICE SENSITIVE	114.47KB	Share
IMU Change of Director's Interest Notice - LC
21/11/18		170.05KB	Share
IMU Appendix 3B and 708A Notice
21/11/18		595.93KB	Share
IMU Change of Director's Interest Notice - PH
21/11/18		170.4KB	Share
IMU Results of Meeting
13/11/18		380.8KB	Share
IMU AGM Presentation
13/11/18		2.26MB	Share
IMU Imugene Advances to Phase 2 in Gastric Cancer Trial
13/11/18	PRICE SENSITIVE	366.09KB	Share
IMU Imugene Receives $1.85 million R&D Tax Incentive
09/11/18	PRICE SENSITIVE	101.15KB	Share
IMU Appendix 4C - quarterly
30/10/18	PRICE SENSITIVE	1.05MB	Share
IMU Change of Director's Interest Notice - AH
22/10/18		469.22KB	Share
IMU Appendix 3B (Exercise of Options) and 708A Notice
22/10/18		538.73KB	Share
IMU Notice of Annual General Meeting/Proxy Form
09/10/18		808.28KB	Share
IMU Change in Executive Remuneration
08/10/18		343.88KB	Share
IMU ESMO President joins Imugene Scientific Advisory Board
04/10/18		132.33KB	Share
IMU Imugene appoints leading cancer researcher to SAB
01/10/18		318.23KB	Share
IMU Appendix 4G
28/09/18		162.44KB	Share
IMU Annual Report to shareholders
28/09/18		4.01MB	Share
IMU Imugene commences cGMP manufacture of PD-1 cancer vaccine
21/09/18	PRICE SENSITIVE	141.95KB	Share
IMU Imugene appoints gastrointestinal cancer expert to SAB
18/09/18		59.89KB	Share
IMU Imugene Completes Phase 1b Cancer Vaccine Trial Recruitment
11/09/18	PRICE SENSITIVE	393.79KB	Share
IMU Appendix 4E and Audited Financial Report
31/08/18	PRICE SENSITIVE	539.83KB	Share
IMU Imugene appoints Dr Mark Marino Chief Medical Officer
23/08/18		399.43KB	Share
IMU Appendix 4C - Quarterly and Business Update
31/07/18	PRICE SENSITIVE	555.82KB	Share
IMU 2018 Bioshares Presentation
27/07/18		5.08MB	Share
IMU Change of Director's Interest Notice - LC
24/07/18		36.75KB	Share

REFRESH

First 4 5 6 7 8

(20min delay)
Last 7.5¢		Change -0.001(1.32%)		Mkt cap ! $548.9M

Open	High	Low	Value	Volume
7.7¢	7.8¢	7.5¢	$1.261M	16.55M

Buyers (Bids)

No.	Vol.	Price($)
22	2015361	7.5¢

Sellers (Offers)

Price($)	Vol.	No.
7.6¢	590270	2

View Market Depth

No.	Vol.	Price($)
22	2015361	0.075
12	726088	0.074
14	1344158	0.073
17	1566160	0.072
25	1915656	0.071

Price($)	Vol.	No.
0.076	590270	2
0.077	691936	7
0.078	2331339	10
0.079	1384426	6
0.080	223727	5

Last trade - 16.10pm 08/05/2024 (20 minute delay)


Last 7.5¢		Change -0.001 ( 1.32 %)
Open	High	Low	Volume
7.6¢	7.8¢	7.5¢	8715272
Last updated 15.59pm 08/05/2024 ?

IMU (ASX) Chart

IMUGENE LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories